Method for preparing talipexole

Abstract

The invention discloses a method for preparing talipexole (6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazole [4,5-d]-aza-dihydrochloride). The method comprises the following steps: using ethyl acrylate as starting raw materials; firstly, carrying out addition reaction on the ethyl acrylate and allyl to generate 3-allylamine base ethyl propionate, then reacting with 4-bromobutyrate to generate 4-(allyl(3-ethoxyl-3-oxopropyl)amino) ethyl butyrate; performing the ring closing reaction under the condition of strong base, decarboxylasing under strong acid to generate 1-allyl azacycloheptane-4-ketone;then performing the nuclear bromination to generate 1-allyl-5-bromine azacycloheptane-4-ketone, and finally, reacting with thiourea to generate a target product (formula I). The invention has novel process, short procedures, high reaction yield, low production cost, and larger implementation value and social and economic benefits.

Description

Technical field

[0001] The invention relates to a chemical synthesis method, in particular to a talixol (6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazole[4,5-d]-nitrogen Heterodihydrochloride) preparation method. technical background

[0002] Talixol (6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazole[4,5-d]-azadihydrochloride) is a selective dopamine D2 Receptor agonists can inhibit the release of dopamine in the uninjured area of ​​dopamine nerve endings and reduce dopaminergic nerve conduction, that is, by selectively stimulating dopamine D2 receptors in the postsynaptic membrane of the striatum, thereby producing an anti-Parkinson effect.

[0003] Talixol’s first manufacturer was Boehringer Ingelheim, Germany, in 1992, and was officially launched in 1996 as a treatment for Parkinson’s disease. Its structural formula is

[0004]

[0005] There are not many reports on the preparation method of talixol. Its representative method is the addition of ethyl acrylate and benzylamine to gene...

Images